A scientific review on Chr. Hansen’s probiotic strain BB-12® has just been published in the peer-reviewed scientific journal "Microorganisms"
The review entitled "The Science behind the Probiotic Strain Bifidobacterium animalis subsp. lactis BB-12®" provides a comprehensive insight into the characteristics and health benefits of the BB-12® probiotic strain. The paper encompasses key data on the BB-12® probiotic strain ― from taxonomy, strain characteristics and mechanisms, to clinical efficacy ― and it concludes that “BB-12® has well-established probiotic characteristics and proven beneficial health effects within gastrointestinal health and immune function.”
In terms of immune function, clinical studies have shown that the BB-12® probiotic strain increases the body’s resistance to common respiratory infections by interacting with the immune system. Furthermore, survival of the BB-12® probiotic strain through the gastrointestinal tract has been demonstrated and the BB-12® probiotic strain has been shown to support a healthy gastrointestinal microbiota.
The world’s most documented probiotic Bifidobacterium
“The BB-12® probiotic strain has been described in numerous scientific publications out of which more than 130 are publications of human clinical studies covering a variety of consumer groups from newborn preterm infants to elderly across various health areas. More than 200 publications are available via the Medline/PubMed publication database.
Other main probiotic bifidobacteria strains have less than 50 publications on the database. This makes Bifidobacterium animalis subsp. lactis (BB-12®) the world’s best documented probiotic Bifidobacterium,” explains Mikkel Jungersen MSc, Scientific Advisor, Scientific Affairs, Human Health & Nutrition.
All information in one document
“We expect our customers to warmly welcome the fact that all relevant information about the BB-12® probiotic strain is now compiled in one document”, says Lasse Nagell, Vice President, Global Sales & Marketing, Human Health & Nutrition.
“A lot of information is available on probiotics today. However the information varies a lot from strain to strain and from supplier to supplier so the reader may be left with a very fragmented picture. The review of the BB-12® probiotic strain is a valuable tool communicating clear facts and data about this specific strain,” Lasse Nagell concludes.
The review was published in Microorganisms (2014, 2(2), 92-110) in a Special Issue "Advances and New Perspectives in Microbial Research". The paper is open-access and can be read here: http://www.mdpi.com/2076-2607/2/2/92
The review, which is authored by Chr. Hansen scientists, finds that beneficial health effects of the BB-12® probiotic strain have been demonstrated through extensive clinical research. The BB-12® probiotic strain has been shown to improve bowel function, to have a protective effect against diarrhea, and to reduce side effects of antibiotic treatment.
Bifidobacterium BB-12®: safety and origin
- Originates from Chr. Hansen’s collection of dairy cultures
- Identified as Bifidobacterium animalis subsp. lactis
- Used worldwide since 1985 with no reported adverse events
- Tested in clinical studies with no reported adverse events
- GRAS (Generally Recognized As Safe) notified by FDA
- QPS (Qualified Presumption of Safety) granted by EFSA
Chr. Hansen is a leading, global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. We develop and produce cultures, enzymes, probiotics and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements and even animal feed and plant protection. Our product innovation is based on more than 30,000 microbial strains – we like to refer to them as ‘good bacteria’. Our solutions enable food manufacturers to produce more with less – while also reducing the use of chemicals and other synthetic additives – which make our products highly relevant in today’s world. We have been delivering value to our partners – and, ultimately, end consumers worldwide – for over 140 years. We are proud that more than one billion people consume products containing our natural ingredients every day. Revenue in the 2017/18 financial year was EUR 1,097 million. Chr. Hansen was founded in 1874 and is listed on Nasdaq Copenhagen.